TRT & TRAVERSE Trial: What the Definitive Study Means

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

The TRAVERSE trial confirmed TRT does not increase major cardiovascular events in high-risk hypogonadal men. This landmark study provides strong evidence for TRT's cardiovascular safety, though vigilance for other adverse events is still needed.

TRT and the TRAVERSE Trial: What It Means for You

The TRAVERSE trial stands as a pivotal moment in the understanding of Testosterone Replacement Therapy (TRT) and its cardiovascular safety. For years, concerns lingered about whether TRT might increase the risk of heart attacks, strokes, or other major cardiovascular events. The TRAVERSE trial, a large-scale, rigorous study, was designed to provide a definitive answer, and its findings have significant implications for both patients and clinicians.

Before TRAVERSE, the data on TRT and cardiovascular risk was mixed. Some observational studies suggested an elevated risk, leading to regulatory warnings and a cautious approach to prescribing TRT, especially in men with pre-existing heart conditions. This created a dilemma: men with symptomatic hypogonadism often experienced significant improvements in quality of life with TRT, but the potential cardiovascular risks were a major deterrent. The scientific community needed a robust, randomized controlled trial to clarify the situation.

The TRAVERSE trial (Lincoff et al., 2023) was a multicenter, randomized, double-blind, placebo-controlled study involving over 5,000 men aged 45 to 80 years with hypogonadism and established cardiovascular disease or a high risk for it. Participants were randomized to receive either testosterone gel or placebo. The primary endpoint was the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

The key finding from TRAVERSE was clear: testosterone replacement therapy was noninferior to placebo with respect to the incidence of MACE. In simpler terms, TRT did not increase the risk of heart attacks, strokes, or cardiovascular death in this high-risk population. This is a powerful reassurance for men who need TRT but have been hesitant due to cardiovascular concerns.

While the primary endpoint showed no increased risk, the trial did identify a higher incidence of certain secondary adverse events in the testosterone group, specifically atrial fibrillation, acute kidney injury, and pulmonary embolism. These findings underscore the importance of careful patient selection and ongoing monitoring during TRT. It means that while the major cardiovascular events are not a concern, clinicians still need to be vigilant for these other potential issues.

The significance of the TRAVERSE trial cannot be overstated. It provides the highest level of evidence to date regarding the cardiovascular safety of TRT. Unlike previous observational studies, which can only show associations and are prone to confounding factors, TRAVERSE was designed to establish causality. Its large size, long duration (median follow-up of 33 months), and focus on a high-risk population make its conclusions highly credible.

For men with symptomatic hypogonadism, the TRAVERSE trial means that the benefits of TRT in improving symptoms like low libido, fatigue, and mood disturbances can be pursued without undue fear of major cardiovascular harm. It empowers physicians to prescribe TRT with greater confidence, provided they adhere to appropriate screening and monitoring protocols. This is a significant shift from the previous era of uncertainty and caution.

The practical takeaway is that the TRAVERSE trial has largely settled the debate on TRT and major cardiovascular risk. If you are a man with diagnosed low testosterone, even with existing heart conditions or risk factors, you can discuss TRT with your doctor with the knowledge that current robust evidence indicates it does not increase your risk of heart attack or stroke. However, diligent monitoring for other potential side effects, such as atrial fibrillation or erythrocytosis, remains essential to ensure safe and effective treatment.